Partner Headlines - AMGN

  1. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, ...

    Investors Business Daily
  2. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  3. Chardan Upgrades Regeneron Amid Relative Underperformance To ...

    Benzinga
  4. Gilead, Johnson & Johnson or Roche?

    GuruFocus
  5. Amgen, Celgene Buck Short Interest Trend In Biotech Stocks

    Benzinga
  6. Chardan: Sell Regeneron After Sanofi Drops Patent Infringement ...

    Benzinga
  7. The Generic Drug Battle

    Benzinga
  8. Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch

    IBD
  9. Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, ...

    Benzinga
  10. Pharmaceuticals Turn To Politics To Protect Prices

    Benzinga
  11. Leerink Is Back On Board The Biotech Train

    Benzinga
  12. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD
  13. Plenty of Opportunity to Buy Individual Stocks: John Buckingham

    GuruFocus
  14. Maybe Some Good News For A Big Biotech ETF

    Benzinga
  15. Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours

    Benzinga
  16. Earnings Recap For January 28

    Benzinga
  17. FDA Accepts Amgen's Biosimilar Biologics License Application ...

    Benzinga
  18. Regeneron Is Now A Sell For Chardan

    Benzinga
  19. Big Earnings Expectations For Big Biotech

    Benzinga
  20. Amgen's Vectibix, Best Supportive Care Improves Overall Survival ...

    Benzinga
  21. Amgen's Repatha) Approved in Japan as First PCSK9 Inhibitor for ...

    Benzinga
  22. Medicines Company Spikes On Report Of Possible Sale

    IBD
  23. Jim Cramer Likes Amgen

    Benzinga
  24. Write A Prescription For This Healthcare ETF

    Benzinga
  25. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD
  26. Stocks, Mutual Funds Rose In Q4 Despite Dec. Woes

    IBD
  27. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga
  28. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  29. Mid-Afternoon Market Update: Netflix Drops Following Baird Downgrade; ...

    Benzinga
  30. Mid-Day Market Update: Baxalta Shares Surge Amid Report Of Shire ...

    Benzinga
  31. Mid-Morning Market Update: Markets Open Lower; Tesla Motors Delivers ...

    Benzinga
  32. Benzinga's Top #PreMarket Gainers

    Benzinga
  33. Alan Fournier Sells GM, Buys Molson Coors Brewing

    GuruFocus
  34. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  35. Dividend Growth Skids To Halt For S&P 500

    IBD
  36. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  37. Benzinga's M&A Chatter for Monday December 21, 2015

    Benzinga
  38. Big Cap 20 Stocks Setting Up In Bases

    IBD
  39. Analyzing Amgen's Dividend Hike

    GuruFocus
  40. 3 Biotechs Atlantic Equities Loves And 1 It's Avoiding

    Benzinga
  41. Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma ...

    Benzinga
  42. EC Approves Amgen's IMLYGIC as First Oncolytic Immunotherapy ...

    Benzinga
  43. 4 Top Dividend Plays To Help Cure Stock Price Blues

    IBD
  44. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD
  45. Allergan Among Health Care Holdings in Alan Fournier's Portfolio

    GuruFocus
  46. Benzinga's Top Upgrades

    Benzinga
  47. Benzinga's Top #PreMarket Gainers

    Benzinga
  48. Amgen Shares Move Higher Following Morgan Stanley Upgrade To ...

    Benzinga
  49. Amgen Submits Application to EMA To Expand Indication Of Kyprolis ...

    Benzinga
  50. Amgen Announces New Analyses Presented At #ASH2015 Demonstrate ...

    Benzinga
  51. Amgen Announces Pivotal Head-To-Head ENDEAVOR Study Results Published ...

    Benzinga
  52. Amgen, Merck target cancer

    IBD
  53. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD
  54. LinkedIn, Palo Alto, Regeneron Profit Estimates Rising

    IBD
  55. Application for Amgen's Biosimilar Candidate to Humira, Submitted ...

    Benzinga
  56. Benzinga's M&A Chatter for Tuesday December 1, 2015

    Benzinga
  57. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  58. EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia ...

    Benzinga
  59. CVS Makes Amgen New BFF

    IBD
  60. CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi

    IBD
  61. European Commission Approves Kyprolis® (carfilzomib) For Combination ...

    Benzinga
  62. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  63. Regeneron Tests Buy Point As New Drug Shows Promise

    IBD
  64. Regeneron Recovers From Clinton Biotech Beat Down

    IBD
  65. Benzinga's M&A Chatter for Tuesday November 10, 2015

    Benzinga
  66. Amgen Issues Presentation of Results from Phase 3 Study Showing ...

    Benzinga
  67. Amgen Announces Etelcalcetide Met Primary Endpoint of Non-Inferiority ...

    Benzinga
  68. ICYMI: Berkshire Hathaway Just Reported Earnings Of $2,769 Per ...

    Benzinga
  69. ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

    Benzinga
  70. Regeneron Q3 Beats Views, But Praluent Launch Slow

    IBD
  71. AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance

    IBD
  72. 10 Stocks To Watch For October 29, 2015

    Benzinga
  73. Buffalo Wild, GoPro Among Flurry Of Late Wed. Earnings

    IBD
  74. Amgen Crushes EPS Views

    IBD
  75. Amgen Q3 Earnings Beat; Sales Growth Best In Years

    IBD
  76. Amgen Posts Upbeat Q3 Results, Lifts Forecast

    Benzinga
  77. Lifelock, Yelp Surge Following Earnings Report; B-Dubs, GoPro ...

    Benzinga
  78. Wild Short Interest Swings For Three Top Biotech Stocks

    Benzinga
  79. Keep an Eye on These 10 Stocks for October 28, 2015

    Benzinga
  80. Stocks End Lower; Apple Up, Twitter Down After Hours

    IBD
  81. Amgen and Cytokinetics Announce Positive Top-Line Results From ...

    Benzinga
  82. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  83. 10 S&P 100 Companies Paying The Highest And Lowest Taxes

    Benzinga
  84. Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene ...

    Benzinga
  85. Cowen: In Biotech Earnings We Trust

    Benzinga
  86. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  87. Valeant Subpoenaed By Federal Prosecutors On Pricing

    IBD
  88. Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy ...

    Benzinga
  89. Eli Lilly Pulls Cholesterol Drug

    IBD
  90. AMGEN

    IBD
  91. After-Hours Action: JetBlue, Amgen, Medtronic

    IBD
  92. New Exploratory Analysis Showed Romosozumab Increased Estimated ...

    Benzinga
  93. Regeneron Stock Pops But Hits Resistance At 50-Day

    IBD
  94. Lilly Kills 'High Risk/High Reward' Cholesterol Drug

    IBD
  95. Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives

    Benzinga
  96. Amgen Announces New Data Show Greater Bone Mineral Density Gains ...

    Benzinga
  97. Benzinga's M&A Chatter for Wednesday October 7, 2015

    Benzinga
  98. A Cholesterol Drug Revolution

    IBD
  99. Amgen's 1990 Base Breakout Launched Major Price Move

    IBD
  100. Stocks Fade After Solid Start; Tesla, Adobe Weigh On Nasdaq

    IBD
Trading Center